Botulinum Toxin for Hyperhidrosis of Areas Other than the Axillae and Palms/Soles

Glaser, Dee Anna; Galperin, Timur A.

doi:10.1016/j.det.2014.06.001

Cited by 15 publications

(14 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many treatment modalities were suggested in the past, however the disease is still recalcitrant to conventional therapy and significantly damage the quality of life of all patients. Since botulinum toxin decreases sweat production it is used for the treatment of hyperhidrosis (de Almeida & Montagner, ; Glaser & Galperin, ). This effect and the subsequent decrease of microorganism colonization might serve as one explanation for its efficacy in the treatment of Hailey–Hailey disease (Benohanian, ).…”

Section: Discussionmentioning

confidence: 99%

“…This effect and the subsequent decrease of microorganism colonization might serve as one explanation for its efficacy in the treatment of Hailey–Hailey disease (Benohanian, ). Botulinum toxin cannot cross the stratum corneum, therefore, its injection is required for both the treatment of hyperhidrosis (de Almeida & Montagner, ; Glaser & Galperin, ) and for the treatment of Hailey–Hailey disease (Charlton et al, ; Friedman et al, ; Kothapalli & Caccetta, ; Lapiere et al, ). It is an effective treatment but a painful, expensive, and the duration effects is for several months only.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

An enhanced transcutaneous delivery of botulinum toxin for the treatment of Hailey–Hailey disease

Bar‐Ilan

Koren

Shehadeh

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

Successful treatment of Hailey-Hailey disease with intradermal botulinum toxininjections has been previously reported. The main disadvantages of this treatment are the excruciating pain and the risk of infections due to the numerous injections.We sought to evaluate the clinical effectiveness and safety profile of a novel approach using an energy-based device (Tixel, Novoxel, and Israel), followed by the topical application of botulinum toxin Type A for the treatment of Hailey-Hailey disease. A retrospective study of all cases of histologically diagnosed cases of Hailey-Hailey disease treated with Tixel device followed by topical application of botulinum toxin between 2018 and 2019 was performed. Epidemiologic, clinical, and treatment data, including effectiveness score and safety, were reviewed. The study included eight patients, of whom seven patients (87.5%) showed good or partial response. No systemic or local adverse effects were reported. There was no difference in effectivity between different body areas. Response to treatment ranged between patients with an average duration of 7.125 months after the second treatment. Tixel treatment followed by topical application of botulinum toxin can be considered in the treatment of Hailey-Hailey disease. This approach is less invasive, less painful, and yet effective as well as safe.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

An enhanced transcutaneous delivery of botulinum toxin for the treatment of Hailey–Hailey disease

Bar‐Ilan

Koren

Shehadeh

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…BotNT injected directly into the axilla suppresses axillary hyperhidrosis for as along as 6 months [Naumann and Lowe 2001;Dressler et al 2002;Glaser 2006;Lowe et al 2007;Paracka et al 2015]; also palmar and plantar hyperhidrosis ]; and of areas other than the axillae and palms/soles [Glaser and Galperin 2014;see Naumann et al 2008;Naumann et al 2013;Dressler 2014].…”

Section: Secretory Disordersmentioning

confidence: 98%

Botulinum neurotoxin: Progress in negating its neurotoxicity; and in extending its therapeutic utility via molecular engineering. MiniReview

Kostrzewa

Kostrzewa³

2015

Peptides

View full text Add to dashboard Cite

“…According to international guidelines, botulinum toxin (Btx) type A is the second‐line treatment for hyperhidrosis if local antiperspirants (aluminum and zirconium salts) fail or are inappropriate . Btx has a strong inhibitory effect on sweating . However, Btx type A injections in the forehead and central face may elicit undesirable local muscle weakness, especially in elderly women with less facial muscle volume.…”

Section: Introductionmentioning

confidence: 99%

“…Btx has a strong inhibitory effect on sweating . However, Btx type A injections in the forehead and central face may elicit undesirable local muscle weakness, especially in elderly women with less facial muscle volume. This problem has partly been solved by using Btx type B, which has a weaker effect on muscles compared with Btx type A, but still has a strong sudomotor inhibition .…”

Section: Introductionmentioning

confidence: 99%

Postmenopausal craniofacial hyperhidrosis treated with botulinum toxin type B

Cabreus¹,

Swartling

Rystedt³

2019

The Journal of Dermatology

View full text Add to dashboard Cite

Hyperhidrosis can seriously impair patients’ quality of life. Medical history, including heredity and hyperhidrosis during youth, as well as current age and time elapsed since menopause, is important to consider when distinguishing between postmenopausal hyperhidrosis and vasomotor symptoms to enable adequate treatment. This report concerns a subgroup of eight postmenopausal patients participating in a randomized controlled trial regarding botulinum toxin (Btx) type B treatment in craniofacial hyperhidrosis. Even though the sample size is small and the enrolment is not yet completed, the promising data collected hitherto are interesting to present in advance because this subtype of craniofacial hyperhidrosis is often underrecognized and challenging to treat. Patients were randomized to receive Btx type B or placebo. Measurements were performed before treatment and 3 ± 1 weeks after. The Dermatology Life Quality Index (DLQI) score was improved for all patients after Btx type B treatment (n = 3) with a median decrease of 9 points (90% median improvement). The placebo group (n = 5) had a median increase of 2 points (–18% median decline). When the same group (n = 5) received Btx type B (open) the DLQI score decreased with a median of 7 points compared with baseline (91% median improvement). Treatment‐related adverse events were temporary and did not prevent improvement of life quality. Furthermore, background data evaluation uncovered interesting findings regarding vasomotor symptoms in relation to postmenopausal hyperhidrosis. In conclusion, the results indicated that Btx type B seems to be a safe and effective treatment in postmenopausal craniofacial hyperhidrosis. Further research is encouraged.

show abstract

Botulinum Toxin for Hyperhidrosis of Areas Other than the Axillae and Palms/Soles

Cited by 15 publications

References 27 publications

An enhanced transcutaneous delivery of botulinum toxin for the treatment of Hailey–Hailey disease

An enhanced transcutaneous delivery of botulinum toxin for the treatment of Hailey–Hailey disease

Botulinum neurotoxin: Progress in negating its neurotoxicity; and in extending its therapeutic utility via molecular engineering. MiniReview

Postmenopausal craniofacial hyperhidrosis treated with botulinum toxin type B

Contact Info

Product

Resources

About